

therefor:

--BRIEF SUMMARY OF THE INVENTION

A2 The present invention includes hypocholesteremic preparations comprising phytosterol esters of conjugated fatty acids, and methods of reducing serum cholesterol levels in mammals through administration of such preparations.--

At page 3, before line 1 thereof, insert:

--DETAILED DESCRIPTION OF THE INVENTION--

At page 7, line 34 thereof, delete "Commercial applicability".

Please add new page 11, which is attached hereto, containing an Abstract of the Disclosure, following the claims.

In the Claims:

Please add new claims 11-30, as follow:

1 --11. (New) A method of reducing serum cholesterol content in a mammal, said method comprising:

A3 (i) providing a hypocholesteremic preparation comprising at least one phytosterol ester of a conjugated fatty acid having from about 6 to about 24 carbon atoms; and

(ii) administering the hypocholesteremic preparation to a mammal in an amount effective to reduce serum cholesterol content in the mammal.--

2 --12. (New) The method according to claim 11, wherein the at least one phytosterol ester comprises an ester of  $\beta$ -sitosterol or  $\beta$ -sitostanol.--

3 --13. (New) The method according to claim 11, wherein the conjugated fatty

**Preliminary Amendment of U.S. National Stage for International Application  
PCT/EP98/07057 filed November 5, 1998**

acid is selected from the group consisting of conjugated linoleic acid and conjugated fish fatty acids.--

<sup>4</sup>  
--14. (New) The method according to claim 11, wherein the conjugated fatty acid comprises conjugated linoleic acid.--

<sup>5</sup>  
--15. (New) The method according to claim 11, wherein the at least one phytostenol ester comprises an ester of conjugated linoleic acid and  $\beta$ -sitostenol or  $\beta$ -sitostanol.--

<sup>6</sup>  
--16. (New) The method according to claim 11, wherein the hypocholesteremic preparation further comprises a potentiating agent selected from the group consisting of tocopherols, chitosans, phytostenol sulfates, (deoxy)ribonucleic acids, and combinations thereof.--

<sup>7</sup>  
--17. (New) The method according to claim 11, wherein the hypocholesteremic preparation further comprises a tocopherol.--

<sup>8</sup>  
--18. (New) The method according to claim 11, wherein the hypocholesteremic preparation further comprises a chitosan selected from low-molecular weight chitosans and high-molecular weight chitosans.--

<sup>9</sup>  
--19. (New) The method according to claim 11, wherein the hypocholesteremic preparation is encapsulated in gelatin, whereby a gelatin capsule is provided, prior to administering the preparation to the mammal.--

<sup>10</sup>  
--20. (New) The method according to claim 18, wherein the at least one phytostenol ester is present in an amount of from about 0.1 to about 50% by weight, based on

Preliminary Amendment of U.S. National Stage for International Application  
PCT/EP98/07057 filed November 5, 1998

the total weight of the gelatin capsule.--

<sup>11</sup>  
--~~21~~. (New) A hypocholesteremic preparation comprising at least one  
phytostenol ester of a conjugated fatty acid having from about 6 to about 24 carbon atoms.--

<sup>12</sup>  
--~~22~~. (New) The hypocholesteremic preparation according to claim ~~21~~,<sup>10</sup>  
wherein the at least one phytostenol ester comprises an ester of  $\beta$ -sitostenol or  $\beta$ -sitostanol.--

<sup>13</sup>  
--~~23~~. (New) The hypocholesteremic preparation according to claim ~~21~~,<sup>10</sup>  
wherein the conjugated fatty acid is selected from the group consisting of conjugated linoleic  
acid and conjugated fish fatty acids.--

<sup>14</sup>  
--~~24~~. (New) The hypocholesteremic preparation according to claim ~~21~~,<sup>10</sup>  
wherein the conjugated fatty acid comprises conjugated linoleic acid.--

<sup>15</sup>  
--~~25~~. (New) The hypocholesteremic preparation according to claim ~~21~~,<sup>10</sup>  
wherein the at least one phytostenol ester comprises an ester of conjugated linoleic acid and  $\beta$ -  
sitostenol or  $\beta$ -sitostanol.--

<sup>16</sup>  
--~~26~~. (New) The hypocholesteremic preparation according to claim ~~21~~,<sup>10</sup>  
wherein the hypocholesteremic preparation further comprises a potentiating agent selected  
from the group consisting of tocopherols, chitosans, phytostenol sulfates, (deoxy)ribonucleic  
acids, and combinations thereof.--

<sup>17</sup>  
--~~27~~. (New) The hypocholesteremic preparation according to claim ~~21~~,<sup>10</sup>  
wherein the hypocholesteremic preparation further comprises a tocopherol.--

<sup>18</sup>  
--~~28~~. (New) The hypocholesteremic preparation according to claim ~~21~~,<sup>10</sup>